


TREATMENT SCHEMA

This is an international multi-centre, randomized, non-inferiority phase III trial evaluating regional radiotherapy (RT) [defined as RT to regional nodes following breast conserving surgery (BCS) or RT to the chestwall and regional nodes following mastectomy] in patients with ER +ve biomarker low risk breast cancer (BC) [defined as Oncotype DX recurrence score  $\leq 25$ ] and limited nodal disease or T3N0 that have had BCS, or mastectomy and will receive endocrine therapy for 5 years. Patients treated by axillary dissection may have 1-3 positive axillary nodes (macrometastases, > 2 mm) regardless of type of surgery (BCS or mastectomy). Patients treated by sentinel lymph node biopsy (SLNB) alone may have 1-2 positive nodes (macrometastases, > 2mm). Patients with disease limited to nodal micrometastases are eligible.

Stratification

- Surgery type (BCS or mastectomy)
- Axillary dissection (yes or no)
- Adjuvant chemotherapy (yes or no)
- Lymphovascular invasion (yes or no)
- Oncotype DX score (0–10, 11-17, or 18-25)



N = 2140 patients